Nasdaq’s SWOT analysis: stock transformation draws analyst upgrades By Investing.com

Nasdaq reported Q4 2025 EPS of $0.96, about 5% above expectations, supported by broad-based revenue strength despite higher operating expenses. Analysts see 9% revenue CAGR through 2027 and EPS rising from $2.82 in 2024 to $4.42 in 2027, with EBITDA margins expanding from 58.2% to 60.6%. The lack of specific FY26 guidance and rising costs temper the upbeat view, but the strategic shift toward higher-margin information services supports a constructive long-term outlook.

Analysis

NDAQ is at the point where the market has to decide whether to pay up for a software-like mix shift or keep discounting it as a cyclical exchange operator. The key second-order effect is that every incremental dollar of recurring data/compliance revenue should be worth materially more than a dollar of transaction revenue, so the valuation rerating can continue even if topline growth only stays mid-single digits. That said, the current setup is fragile: margin expansion is the whole story, and if operating expense growth remains elevated for even 2-3 quarters, the multiple can compress faster than earnings grow.

The competitive read-through is more interesting than the headline. A stronger NDAQ in regulatory tech and indices does not just pressure CME/CBOE/ICE on trading, it also forces them to defend adjacent data and workflow budgets where customer switching costs are low and bundling matters. In practice, that means the real fight is for wallet share in compliance, analytics, and benchmark licensing, not exchange volume; the winner will be whoever can cross-sell into existing institutional relationships fastest without bloating sales spend.

The contrarian risk is that this is already a good business being re-rated for a transformation that may take longer than investors expect. Without explicit FY26 guidance, the stock is vulnerable to any sign that “investment for growth” is actually a structural step-up in opex, especially if capital markets activity cools and removes the cyclical tailwind. On the other hand, the selloff case is not obvious: if margins just hold near current levels and revenue keeps compounding, the stock can continue to de-risk upward over the next 6-12 months.

Key Decisions for Investors

• Long NDAQ on pullbacks over the next 1-2 weeks; target 10-15% upside over 3-6 months if the market starts underwriting the 2027 earnings power rather than the missing FY26 guide. Risk: a single quarter of opex acceleration can knock 8-12% off the multiple.
• Pair trade: long NDAQ / short ICE or CBOE for 2-4 months. Thesis: NDAQ’s mix shift should drive a better rerating path than peers more exposed to transaction sensitivity; stop if peers show faster recurring-revenue growth or NDAQ misses margin expansion.
• Buy NDAQ Jan-2027 call spreads, funded with nearer-dated upside sales. Use this to express the rerating thesis with defined downside; best payoff if the market assigns an information-services multiple before the 2027 margin target is fully visible.
• Short-dated downside hedge: buy 1-3 month NDAQ puts around earnings if the stock trades near the upper end of its recent range. The stock is vulnerable to guidance disappointment more than to the headline earnings beat.
• Relative value: avoid adding to CME/CBOE/ICE until there is evidence the data/compliance spend cycle is reaccelerating. If NDAQ’s recurring-revenue mix continues improving, the peer group could underperform by 5-8% on a 6-month horizon.